Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 141
Filtrer
1.
AAPS PharmSciTech ; 25(7): 190, 2024 Aug 20.
Article de Anglais | MEDLINE | ID: mdl-39164432

RÉSUMÉ

In this research, 3D-printed antifungal buccal films (BFs) were manufactured as a potential alternative to commercially available antifungal oral gels addressing key considerations such as ease of manufacturing, convenience of administration, enhanced drug efficacy and suitability of paediatric patients. The fabrication process involved the use of a semi-solid extrusion method to create BFs from zein-Poly-Vinyl-Pyrrolidone (zein-PVP) polymer blend, which served as a carrier for drug (miconazole) and taste enhancers. After manufacturing, it was determined that the disintegration time for all films was less than 10 min. However, these films are designed to adhere to buccal tissue, ensuring sustained drug release. Approximately 80% of the miconazole was released gradually over 2 h from the zein/PVP matrix of the 3D printed films. Moreover, a detailed physicochemical characterization including spectroscopic and thermal methods was conducted to assess solid state and thermal stability of film constituents. Mucoadhesive properties and mechanical evaluation were also studied, while permeability studies revealed the extent to which film-loaded miconazole permeates through buccal tissue compared to commercially available oral gel formulation. Histological evaluation of the treated tissues was followed. Furthermore, in vitro antifungal activity was assessed for the developed films and the commercial oral gel. Finally, films underwent a two-month drug stability test to ascertain the suitability of the BFs for clinical application. The results demonstrate that 3D-printed films are a promising alternative for local administration of miconazole in the oral cavity.


Sujet(s)
Antifongiques , Candidose buccale , Libération de médicament , Miconazole , Impression tridimensionnelle , Miconazole/administration et posologie , Miconazole/composition chimique , Miconazole/pharmacocinétique , Antifongiques/administration et posologie , Antifongiques/composition chimique , Antifongiques/pharmacocinétique , Administration par voie buccale , Candidose buccale/traitement médicamenteux , Humains , Zéine/composition chimique , Muqueuse de la bouche/métabolisme , Muqueuse de la bouche/microbiologie , Povidone/composition chimique , Perméabilité , Systèmes de délivrance de médicaments/méthodes , Animaux , Chimie pharmaceutique/méthodes , Enfant
2.
Int J Pharm ; 661: 124461, 2024 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-38996824

RÉSUMÉ

Since the local treatment of oral candidiasis usually requires long-term administration of the antifungal drug, an ideal dosage form should be able to maintain the drug release over an extended period, assuring an adequate concentration at the infection site. In this context, we have considered the possibility of a buccal delivery of miconazole nitrate (MN) by mucoadhesive polymeric matrices. The loading of the antifungal drug in a hydrophilic matrix was made possible by taking advantage of the amphiphilic nature of liposomes (LP). The MN-loaded LP were prepared by a thin film evaporation method followed by extrusion, while solid matrices were obtained by freeze-drying a suspension of the LP in a polymeric solution based on chitosan (CH), sodium hyaluronate (HYA), or hydroxypropyl methylcellulose (HPMC). MN-loaded LP measured 284.7 ± 20.1 nm with homogeneous size distribution, adequate drug encapsulation efficiency (86.0 ± 3.3 %) and positive zeta potential (+47.4 ± 3.3). CH and HYA-based formulations almost completely inhibited C. albicans growth after 24 h, even if the HYA-based one released a higher amount of the drug. The CH-based matrix also provided the best mucoadhesive capacity and therefore represents the most promising candidate for the local treatment of oral candidiasis.


Sujet(s)
Antifongiques , Candida albicans , Candidose buccale , Chitosane , Libération de médicament , Dérivés de l'hypromellose , Liposomes , Miconazole , Antifongiques/administration et posologie , Antifongiques/composition chimique , Antifongiques/pharmacocinétique , Miconazole/administration et posologie , Miconazole/composition chimique , Miconazole/pharmacocinétique , Candidose buccale/traitement médicamenteux , Candida albicans/effets des médicaments et des substances chimiques , Dérivés de l'hypromellose/composition chimique , Administration par voie buccale , Chitosane/composition chimique , Chitosane/administration et posologie , Adhésivité , Acide hyaluronique/composition chimique , Acide hyaluronique/administration et posologie , Polymères/composition chimique , Systèmes de délivrance de médicaments , Muqueuse de la bouche/métabolisme , Muqueuse de la bouche/microbiologie
3.
Pak J Pharm Sci ; 37(1): 95-105, 2024 Jan.
Article de Anglais | MEDLINE | ID: mdl-38741405

RÉSUMÉ

Hydrophilic drugs could be incorporated into the skin surface by manes of Lipogel. This study aimed to prepare miconazole lipogel with natural ingredients to enhance drug permeability using dimethyl Sulfoxide (DMSO). The miconazole lipogels, A1 (without DMSO) and A2 (with DMSO) were formulated and evaluated for organoleptic evaluation, pH, viscosity, stability studies, freeze-thawing, drug release profile and drug permeation enhancement. Results had stated that prepared lipogel's pH falls within the acceptable range required for topical delivery (4 to 6) while both formulations show good results in organoleptic evaluation. The A2 formulation containing DMSO shows better permeation of miconazole (84.76%) on the artificial skin membrane as compared to A1 lipogel formulation (50.64%). In in-vitro drug release studies, A2 for-mulation showed 87.48% drug release while A1 showed just 60.1% drug release from lipogel. Stability studies were performed on model formulations under environmental conditions and both showed good spreadibility, stable pH, free of grittiness and good consistency in formulation. The results concluded that A2 formulation containing DMSO shows better results as compared to DMSO-free drug lipogel.


Sujet(s)
Diméthylsulfoxyde , Libération de médicament , Gels , Miconazole , Perméabilité , Miconazole/administration et posologie , Miconazole/composition chimique , Miconazole/pharmacocinétique , Diméthylsulfoxyde/composition chimique , Viscosité , Stabilité de médicament , Concentration en ions d'hydrogène , Absorption cutanée/effets des médicaments et des substances chimiques , Chimie pharmaceutique , Préparation de médicament , Antifongiques/administration et posologie , Antifongiques/composition chimique , Antifongiques/pharmacocinétique , Administration par voie cutanée
4.
Molecules ; 29(9)2024 May 06.
Article de Anglais | MEDLINE | ID: mdl-38731651

RÉSUMÉ

The main objective of this study was to investigate the metabolism of miconazole, an azole antifungal drug. Miconazole was subjected to incubation with human liver microsomes (HLM) to mimic phase I metabolism reactions for the first time. Employing a combination of an HLM assay and UHPLC-HRMS analysis enabled the identification of seven metabolites of miconazole, undescribed so far. Throughout the incubation with HLM, miconazole underwent biotransformation reactions including hydroxylation of the benzene ring and oxidation of the imidazole moiety, along with its subsequent degradation. Additionally, based on the obtained results, screen-printed electrodes (SPEs) were optimized to simulate the same biotransformation reactions, by the use of a simple, fast, and cheap electrochemical method. The potential toxicity of the identified metabolites was assessed using various in silico models.


Sujet(s)
Spectrométrie de masse , Miconazole , Microsomes du foie , Miconazole/composition chimique , Miconazole/métabolisme , Humains , Chromatographie en phase liquide à haute performance/méthodes , Microsomes du foie/métabolisme , Spectrométrie de masse/méthodes , Techniques électrochimiques/méthodes , Antifongiques/composition chimique , Antifongiques/métabolisme , Biotransformation
5.
Int J Mol Sci ; 25(10)2024 May 07.
Article de Anglais | MEDLINE | ID: mdl-38791121

RÉSUMÉ

Melanoma, arguably the deadliest form of skin cancer, is responsible for the majority of skin-cancer-related fatalities. Innovative strategies concentrate on new therapies that avoid the undesirable effects of pharmacological or medical treatment. This article discusses the chemical structures of [(MTZ)2AgNO3], [(MTZ)2Ag]2SO4, [Ag(MCZ)2NO3], [Ag(MCZ)2BF4], [Ag(MCZ)2SbF6] and [Ag(MCZ)2ClO4] (MTZ-metronidazole; MCZ-miconazole) silver(I) compounds and the possible relationship between the molecules and their cytostatic activity against melanoma cells. Molecular Hirshfeld surface analysis and computational methods were used to examine the possible association between the structure and anticancer activity of the silver(I) complexes and compare the cytotoxicity of the silver(I) complexes of metronidazole and miconazole with that of silver(I) nitrate, cisplatin, metronidazole and miconazole complexes against A375 and BJ cells. Additionally, these preliminary biological studies found the greatest IC50 values against the A375 line were demonstrated by [Ag(MCZ)2NO3] and [(MTZ)2AgNO3]. The compound [(MTZ)2AgNO3] was three-fold more toxic to the A375 cells than the reference (cisplatin) and 15 times more cytotoxic against the A375 cells than the normal BJ cells. Complexes of metronidazole with Ag(I) are considered biocompatible at a concentration below 50 µmol/L.


Sujet(s)
Antinéoplasiques , Complexes de coordination , Mélanome , Métronidazole , Miconazole , Argent , Humains , Mélanome/traitement médicamenteux , Mélanome/métabolisme , Mélanome/anatomopathologie , Miconazole/pharmacologie , Miconazole/composition chimique , Argent/composition chimique , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Métronidazole/composition chimique , Métronidazole/pharmacologie , Lignée cellulaire tumorale , Complexes de coordination/pharmacologie , Complexes de coordination/composition chimique , Survie cellulaire/effets des médicaments et des substances chimiques , Tumeurs cutanées/traitement médicamenteux , Tumeurs cutanées/anatomopathologie
6.
Microb Pathog ; 184: 106312, 2023 Nov.
Article de Anglais | MEDLINE | ID: mdl-37652266

RÉSUMÉ

People with immune deficiency are at risk of developing infections caused by several bacterial and fungal species. In this work, chitosan-coated miconazole was developed by a simple sol-gel method. Miconazole is considered an effective drug to treat vaginal infection-causing bacteria and fungi. The coating of chitosan with miconazole nitrate showed the highest drug loading efficiency (62.43%) and mean particle size (2 µm). FTIR spectroscopic analysis confirmed the entrapment of miconazole nitrate into chitosan polymer. The antifungal result demonstrated that MN@CS microgel possessed notable anti-Aspergillus fumigatus and Candida albicans activity in lower doses. Antibacterial activity results revealed excellent bacterial growth inhibition of MN@CS microgel towards human skin infectious pathogens Escherichia coli and Staphylococcus aureus. The biocompatibility studies of In vitro cell viability and Artemia salina lethality assay suggested that MN@CS microgel is more biosafe and suitable for human external applications. In the future, it will be an efficient anti-inflammatory agent for the treatment of vaginal infections.


Sujet(s)
Candidose vulvovaginale , Chitosane , Microgels , Femelle , Humains , Miconazole/pharmacologie , Miconazole/composition chimique , Miconazole/usage thérapeutique , Candidose vulvovaginale/traitement médicamenteux , Chitosane/composition chimique , Microgels/usage thérapeutique , Antifongiques/pharmacologie , Antifongiques/usage thérapeutique , Antifongiques/composition chimique , Candida albicans , Complications postopératoires
7.
J Pharm Sci ; 112(2): 562-572, 2023 02.
Article de Anglais | MEDLINE | ID: mdl-36096286

RÉSUMÉ

Vaginal candidiasis is a common form of infection in women caused by Candida species. Due to several drawbacks of conventional treatments, the current research is attempted to formulate and optimize a miconazole nitrate-loaded in situ spray gel for vaginal candidiasis. The stimuli-responsive (pH and thermo-responsive) polymers selected for the in situ gel were chitosan and poloxamer 407, respectively, whereas hydroxypropyl methylcellulose (HPMC) was introduced in the formulation to further improve the mucoadhesive property. The dispersion of each polymer was carried out using the cold method, whereas the optimization of the formulation was achieved using Box-Behnken statistical design considering viscosity and gelation temperature as dependent variables. Present design achieved the optimized outcome with HPMC, poloxamer and chitosan at 0.52% (w/v), 18.68% (w/v) and 0.41% (w/v), respectively. Evaluation of drug-excipients compatibility was performed using differential scanning calorimetry, Fourier transform infrared spectroscopy, and thermogravimetric analysis where the results showed the absence of any chemical interaction between the polymers and drug component. The optimized formulation showed gelation temperature at 31°C allowing in situ phase transition in a vaginal environment; pH of 4.21 is suitable for use in the vaginal cavity, and appropriate viscosity (290 cP) at storage temperature (below 30°C) would allow spraying at ease, whereas strong mucoadhesive force (22.4±0.513 g) would prevent leaking of the formulation after application. The drug release profile showed sustained release up to 24 h with a cumulative drug release of 81.72%, which is significantly better than the marketed miconazole nitrate cream. In addition, an improved antifungal activity could be correlated to the sustained release of the drug from the formulation. Finally, the safety of the formulation was established while tested on HaCaT cell lines. Based on our findings, it could be concluded that the in situ hydrogel formulation using stimuli-responsive polymers could be a viable alternative to the conventional dosage form that can help to reduce the frequency of administration with ease of application to the site of infection, thus will provide better patient compliance.


Sujet(s)
Candidose vulvovaginale , Chitosane , Femelle , Humains , Miconazole/composition chimique , Miconazole/usage thérapeutique , Préparations à action retardée/composition chimique , Chitosane/composition chimique , Candidose vulvovaginale/traitement médicamenteux , Antifongiques/composition chimique , Poloxamère/composition chimique , Gels/composition chimique
8.
J Clin Lab Anal ; 35(12): e24085, 2021 Dec.
Article de Anglais | MEDLINE | ID: mdl-34773716

RÉSUMÉ

BACKGROUND: Metabolic abnormalities in patients with gastric adenocarcinoma lead to drug resistance and poor prognosis. Therefore, this study aimed to explore biomarkers that can predict the prognostic risk of gastric adenocarcinoma by analyzing drug metabolism-related genes. METHODS: The RNA-seq and clinical information on gastric adenocarcinoma were downloaded from the UCSC and gene expression omnibus databases. Univariate and least absolute shrinkage and selection operator regression analyses were used to identify the prognostic gene signature of gastric adenocarcinoma. The relationships between gastric adenocarcinoma prognostic risk and tumor microenvironment were assessed using CIBERSORT, EPIC, QUANTISEQ, MCPCounter, xCell, and TIMER algorithms. The potential drugs that could target the gene signatures were predicted in WebGestalt, and molecular docking analysis verified their binding stabilities. RESULTS: Combined with clinical information, an eight-gene signature, including GPX3, ABCA1, NNMT, NOS3, SLCO4A1, ADH4, DHRS7, and TAP1, was identified from the drug metabolism-related gene set. Based on their expressions, risk scores were calculated, and patients were divided into high- and low-risk groups, which had significant differences in survival status and immune infiltrations. Risk group was also identified as an independent prognostic factor of gastric adenocarcinoma, and the established prognostic and nomogram models exhibited excellent capacities for predicting prognosis. Finally, miconazole and niacin were predicted as potential therapeutic drugs for gastric adenocarcinoma that bond stably with NOS3 and NNMT through hydrogen interactions. CONCLUSIONS: This study proposed a drug metabolism-related eight-gene signature as a potential biomarker to predict the gastric adenocarcinoma prognosis risks.


Sujet(s)
Adénocarcinome/génétique , Adénocarcinome/mortalité , Inactivation métabolique/génétique , Tumeurs de l'estomac/génétique , Tumeurs de l'estomac/mortalité , Adénocarcinome/traitement médicamenteux , Adulte , Sujet âgé , Marqueurs biologiques tumoraux/génétique , Glibenclamide/composition chimique , Glibenclamide/métabolisme , Glibenclamide/pharmacocinétique , Humains , Miconazole/composition chimique , Miconazole/pharmacocinétique , Adulte d'âge moyen , Simulation de docking moléculaire , Nomogrammes , Pronostic , Cartes d'interactions protéiques/génétique , Protéines/composition chimique , Protéines/génétique , Reproductibilité des résultats , Facteurs de risque , Tumeurs de l'estomac/traitement médicamenteux , Microenvironnement tumoral/effets des médicaments et des substances chimiques , Microenvironnement tumoral/génétique , Microenvironnement tumoral/immunologie
9.
Int J Mol Sci ; 22(21)2021 Nov 08.
Article de Anglais | MEDLINE | ID: mdl-34769486

RÉSUMÉ

We previously reported that conjugates of antimicrobial peptide fragment analogues and poly (lactic-co-glycolic) acid (PLGA) enhance antimicrobial activity and that the conjugated micelle structure is an effective tool for antimicrobial drug delivery. In recent years, the delivery of antimicrobial peptides to targets for antimicrobial activity has attracted attention. In this study, we targeted Candida albicans, a causative organism of catheter-related bloodstream infections, which is refractory to antimicrobial agents and is currently a problem in medical practice. We evaluated the antifungal activity of CKR12 (a mutant fragment of the human cathelicidin peptide, LL-37)-PLGA-miconazole (MCZ) micelles using nanotechnology with MCZ delivery. The prepared CKR12-PLGA-MCZ micelles were characterised by measuring dynamic light scattering, zeta potential, dilution stability, and drug release. CKR12-PLGA-MCZ micelles showed higher antifungal activity than CKR12-PLGA micelles and MCZ solution. Furthermore, scanning and transmission electron microscopy suggested that CKR12-PLGA-MCZ micelles disrupted both cell wall and cell membrane of C. albicans. Our results revealed a synergistic effect of antifungal activity using a combination of antimicrobial peptide fragment analogues and MCZ, and that MCZ is a promising tool for the delivery to target microorganisms.


Sujet(s)
Peptides antimicrobiens cationiques/pharmacologie , Candida albicans/effets des médicaments et des substances chimiques , Candidose/traitement médicamenteux , Systèmes de délivrance de médicaments/méthodes , Miconazole/pharmacologie , Nanoparticules/composition chimique , Copolymère d'acide poly(lactique-co-glycolique)/composition chimique , Antifongiques/pharmacologie , Peptides antimicrobiens cationiques/composition chimique , Candidose/métabolisme , Candidose/microbiologie , Micelles , Miconazole/composition chimique , Cathélicidines
10.
Future Med Chem ; 13(13): 1105-1125, 2021 07.
Article de Anglais | MEDLINE | ID: mdl-33960203

RÉSUMÉ

Background: Alzheimer's disease is a multifactorial neurological disorder seen in elderly people. Loss of cholinergic transmission and unbalanced tryptophan metabolism kynurenine pathway have been demonstrated in neuropsychiatric diseases. Methods & results: Among the two series of synthesized compounds, compounds 5c and 5h were identified as effective dual BChE/IDO1 inhibitors, with well-balanced micromolar activity. Compounds 5c and 5h exhibited promising ability to ameliorate behavioral impairment by Morris water maze. The safety of miconazole analogs was also validated by PC12 and SH-SY5Y cell lines. Conclusion: These results highlight the ability of 5c and 5h to treat Alzheimer's disease.


Sujet(s)
Maladie d'Alzheimer/traitement médicamenteux , Butyrylcholine esterase/métabolisme , Anticholinestérasiques/pharmacologie , Miconazole/pharmacologie , Neuroprotecteurs/pharmacologie , Maladie d'Alzheimer/métabolisme , Peptides bêta-amyloïdes/antagonistes et inhibiteurs , Peptides bêta-amyloïdes/métabolisme , Animaux , Comportement animal/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Anticholinestérasiques/synthèse chimique , Anticholinestérasiques/composition chimique , Electrophorus , Equus caballus , Humains , Mâle , Souris , Miconazole/synthèse chimique , Miconazole/composition chimique , Modèles moléculaires , Neuroprotecteurs/synthèse chimique , Neuroprotecteurs/composition chimique , Cellules PC12 , Fragments peptidiques/antagonistes et inhibiteurs , Fragments peptidiques/métabolisme , Agrégats de protéines/effets des médicaments et des substances chimiques , Rats
11.
Eur J Med Chem ; 216: 113337, 2021 Apr 15.
Article de Anglais | MEDLINE | ID: mdl-33713977

RÉSUMÉ

A series of selenium-containing miconazole derivatives were identified as potent antifungal drugs in our previous study. Representative compound A03 (MIC = 0.01 µg/mL against C.alb. 5314) proved efficacious in inhibiting the growth of fungal pathogens. However, further study showed lead compound A03 exhibited potential hemolysis, significant cytotoxic effect and unfavorable metabolic stability and was therefore modified to overcome these drawbacks. In this article, the further optimization of selenium-containing miconazole derivatives resulted in the discovery of similarly potent compound B17 (MIC = 0.02 µg/mL against C.alb. 5314), exhibiting a superior pharmacological profile with decreased rate of metabolism, cytotoxic effect and hemolysis. Furthermore, compound B17 showed fungicidal activity against Candida albicans and significant effects on the treatment of resistant Candida albicans infections. Meanwhile, compound B17 not only could reduce the ergosterol biosynthesis pathway by inhibiting CYP51, but also inhibited biofilm formation. More importantly, compound B17 also shows promising in vivo efficacy after intraperitoneal injection and the PK study of compound B17 was evaluated. In addition, molecular docking studies provide a model for the interaction between the compound B17 and the CYP51 protein. Overall, we believe that these selenium-containing miconazole compounds can be further developed for the potential treatment of fungal infections.


Sujet(s)
Inhibiteurs de la 14-alpha déméthylase/composition chimique , Antifongiques/composition chimique , Miconazole/composition chimique , Sélénium/composition chimique , Sterol 14-demethylase/composition chimique , Inhibiteurs de la 14-alpha déméthylase/métabolisme , Inhibiteurs de la 14-alpha déméthylase/pharmacologie , Inhibiteurs de la 14-alpha déméthylase/usage thérapeutique , Animaux , Antifongiques/métabolisme , Antifongiques/pharmacologie , Antifongiques/usage thérapeutique , Sites de fixation , Biofilms/effets des médicaments et des substances chimiques , Candida/effets des médicaments et des substances chimiques , Candida/physiologie , Candidose/traitement médicamenteux , Candidose/anatomopathologie , Lignée cellulaire tumorale , Survie cellulaire/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Conception de médicament , Période , Humains , Souris , Miconazole/métabolisme , Miconazole/pharmacologie , Miconazole/usage thérapeutique , Tests de sensibilité microbienne , Simulation de docking moléculaire , Sterol 14-demethylase/métabolisme , Relation structure-activité
12.
Int J Mol Sci ; 22(4)2021 Feb 03.
Article de Anglais | MEDLINE | ID: mdl-33546211

RÉSUMÉ

In a previous article, we reported on the higher toxicity of silver(I) complexes of miconazole [Ag(MCZ)2NO3 (1)] and [Ag(MCZ)2ClO4 (2)] in HepG2 tumor cells compared to the corresponding salts of silver, miconazole and cisplatin. Here, we present the synthesis of two silver(I) complexes of miconazole containing two new counter ions in the form of Ag(MCZ)2X (MCZ = 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole]; X = BF4- (3), SbF6- (4)). The novel silver(I) complexes were characterized by elemental analysis, 1H NMR, 13C NMR and infrared (IR) spectroscopy, electrospray ionization (ESI)-MS spectrometry and X-ray-crystallography. In the present study, the antimicrobial activity of all obtained silver(I) complexes of miconazole against six strains of Gram-positive bacteria, five strains of Gram-negative bacteria and yeasts was evaluated. The results were compared with those of a silver sulfadiazine drug, the corresponding silver salts and the free ligand. Silver(I) complexes exhibited significant activity against Gram-positive bacteria, which was much better than that of silver sulfadiazine and silver salts. The highest antimicrobial activity was observed for the complex containing the nitrate counter ion. All Ag(I) complexes of miconazole resulted in much better inhibition of yeast growth than silver sulfadiazine, silver salts and miconazole. Moreover, the synthesized silver(I) complexes showed good or moderate activity against Gram-negative bacteria compared to the free ligand.


Sujet(s)
Antibactériens/pharmacologie , Antifongiques/pharmacologie , Complexes de coordination/synthèse chimique , Miconazole/composition chimique , Argent/composition chimique , Complexes de coordination/composition chimique , Complexes de coordination/pharmacologie , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Levures/effets des médicaments et des substances chimiques
13.
AAPS PharmSciTech ; 21(7): 278, 2020 Oct 08.
Article de Anglais | MEDLINE | ID: mdl-33033939

RÉSUMÉ

People with weakened immune systems are at risk of developing candidiasis which is a fungal infection caused by several species of Candida genus. In this work, polymeric nanoparticles containing miconazole nitrate and the anesthetic lidocaine clorhydrate were developed. Miconazole was chosen as a typical drug to treat buccopharyngeal candidiasis whereas lidocaine may be useful in the management of the pain burning, and pruritus caused by the infection. Nanoparticles were synthesized using chitosan and gelatin at different ratios ranging from 10:90 to 90:10. The nano-systems presented nanometric size (between 80 and 300 nm in water; with polydispersion index ranging from 0.120 to 0.596), and positive Z potential (between 20.11 and 37.12 mV). The determined encapsulation efficiency ranges from 65 to 99% or 34 to 91% for miconazole nitrate and lidocaine clorhydrate, respectively. X-ray diffraction and DSC analysis suggested that both drugs were in amorphous state in the nanoparticles. Finally, the systems fitted best the Korsmeyer-Peppas model showing that the release from the nanoparticles was through diffusion allowing a sustained release of both drugs and prolonged the activity of miconazole nitrate over time against Candida albicans for at least 24 h.


Sujet(s)
Candida albicans/isolement et purification , Candidose/traitement médicamenteux , Lidocaïne/administration et posologie , Miconazole/administration et posologie , Nanoparticules/composition chimique , Polymères/composition chimique , Antifongiques/administration et posologie , Antifongiques/composition chimique , Calorimétrie différentielle à balayage , Chitosane , Humains , Lidocaïne/composition chimique , Miconazole/composition chimique , Nanoparticules/administration et posologie , Diffraction des rayons X
14.
Ars pharm ; 61(3): 155-162, jul.-sept. 2020. ilus, tab
Article de Espagnol | IBECS | ID: ibc-195117

RÉSUMÉ

INTRODUCCIÓN: las emulsiones son un tipo de preparado farmacéutico muy utilizado en aplicación tópica consistentes en sistemas bifásicos de aceite-agua o agua-aceite, donde el principio activo deseado se incorpora en una de las fases dependiendo de su solubilidad. Diversos estudios demuestran que la estabilidad es mayor en emulsiones con estructuras líquido-cristalinas. El principio activo liposoluble Miconazol, que actúa como antimicótico, se solubiliza en la fase oleosa de la emulsión y en la fracción de la cadena hidrocarbonada de los cristales líquidos. MÉTODO: se utilizaron técnicas microscópicas para analizar las características de una emulsión convencional y de otra con cristales líquidos, a las que se les incorporó el principio activo Miconazol. Se determinaron las dimensiones de las gotas de la fase interna y mediante microscopía de polarización se caracterizaron los cristales líquidos. RESULTADOS: el análisis de las imágenes microscópicas permitió determinar que en las formulaciones con cristales líquidos con y sin Miconazol, aproximadamente el 80 % de las gotas tienen dimensiones en el intervalo 0,5 mim - 1 mim. Las observaciones microscópicas con luz polarizada nos permitieron determinar que los cristales líquidos tienen birrefringencia con la formación de cruces de extinción uniáxicas negativas, las cuales son características de las fases liotrópicas laminares con texturas cónicas focales. CONCLUSIONES: los resultados muestran que el agregado de Miconazol, no interfiere con la formación de la estructura de los cristales líquidos, por lo que estas dependen de los componentes de la formulación y de la técnica de preparación


INTRODUCTION: emulsions are a type of pharmaceutical preparation widely used in topical applications consisting of two-phase systems of oil-in-water or water-in-oil, where the desired active ingredient is incorporated into one of the phases depending on its solubility. Several studies show that stability is greater in emulsions with liquid-crystalline structures. The liposoluble active substance Miconazole, which acts as an antifungal agent, is solubilized in the oil phase of the emulsion as well as in the fraction of the hydrocarbon chain in liquid crystals. METHOD: microscopic techniques were used to analyze the characteristics of both a conventional emulsion and another one containing the liquid crystals. Miconazole was incorporated into both emulsions; drop dimensions in the internal phase were determined and the liquid crystals were characterized by polarization microscopy. RESULTS: through the analysis of the microscopic images of the formulation with liquid crystals with Miconazole and without Miconazole, it was possible to determine that approximately 80% of the drops have dimensions ranging from 0.5 Mum - 1 Mum. Microscopic observations with polarized light allowed us to determine that liquid crystals have birefringence with the formation of negative uniaxial extinction crosses, which are characteristic of laminar lyotropic phases with focal conical textures. CONCLUSIONS: the results show that the addition of Miconazole does not interfere with the formation of the structure of the liquid crystals. Therefore, the formation of liquid crystals depends both on the components of the formulation and the preparation technique


Sujet(s)
Cristaux liquides , Microscopie en lumière polarisée/instrumentation , Émulsions/effets des radiations , Miconazole/composition chimique , Microscopie en lumière polarisée/méthodes , Émulsions/pharmacologie , Miconazole/pharmacologie
15.
Future Med Chem ; 12(20): 1815-1828, 2020 10.
Article de Anglais | MEDLINE | ID: mdl-32787684

RÉSUMÉ

Aim: The identification of drugs for the coronavirus disease-19 pandemic remains urgent. In this manner, drug repurposing is a suitable strategy, saving resources and time normally spent during regular drug discovery frameworks. Essential for viral replication, the main protease has been explored as a promising target for the drug discovery process. Materials & methods: Our virtual screening pipeline relies on the known 3D properties of noncovalent ligands and features of crystalized complexes, applying consensus analyses in each step. Results: Two oral (bedaquiline and glibenclamide) and one buccal drug (miconazole) presented 3D similarity to known ligands, reasonable predicted binding modes and micromolar predicted binding affinity values. Conclusion: We identified three approved drugs as promising inhibitors of the main viral protease and suggested design insights for future studies for development of novel selective inhibitors.


Sujet(s)
Antiviraux/pharmacologie , Betacoronavirus/enzymologie , Infections à coronavirus/traitement médicamenteux , Découverte de médicament , Pneumopathie virale/traitement médicamenteux , Inhibiteurs de protéases/pharmacologie , Protéines virales non structurales/antagonistes et inhibiteurs , Antiviraux/composition chimique , Betacoronavirus/effets des médicaments et des substances chimiques , COVID-19 , Protéases 3C des coronavirus , Infections à coronavirus/virologie , Cysteine endopeptidases/métabolisme , Diarylquinoléines/composition chimique , Diarylquinoléines/pharmacologie , Conception de médicament , Glibenclamide/composition chimique , Glibenclamide/pharmacologie , Humains , Ligands , Miconazole/composition chimique , Miconazole/pharmacologie , Modèles moléculaires , Simulation de docking moléculaire , Pandémies , Pneumopathie virale/virologie , Inhibiteurs de protéases/composition chimique , SARS-CoV-2 , Protéines virales non structurales/métabolisme
16.
Pak J Pharm Sci ; 33(1(Special)): 449-457, 2020 Jan.
Article de Anglais | MEDLINE | ID: mdl-32173643

RÉSUMÉ

Topical candidiasis is a known skin fungal infection which is usually treated by conventional dosage forms such as cream, gel, emulgel which are having numerous adverse effects on skin. To overcome such disadvantages, different novel drug delivery systems have been considered. Polymer based nano-particulate systems have shown good skin penetration after topical application. Therefore, in the present study the main focus was on the pathology, pathogenesis, and consequently topical treatment of candidiasis. Nanogel containing miconazole have been prepared from the natural polymers i.e. gelatin and chitosan. The nanogel of miconazole (100 mg) nitrate was formulated by modified emulsification-diffusion technique and characterized for different parameters. From all the seven nanogel formulations named as F1 to F7, F1 (Gelatin and Chitosan in the percentage of 82.85 and 17.15 respectively) have been selected as model formulations. The reason behind that was as per ICH stability guideline, the formulations F1 was found optimum and stable. Miconazole nanogel formulations F1 also showed the maximum release i.e. 78 % approximately. XRD showed the formulated nanogel was in crystalline shape. In summary, the miconazole nanogel drug delivery systems have two main advantages i.e. they are topical preparation as well as nano sized. It can be postulated that nanogel may be a best approach to treat the fungal skin diseases.


Sujet(s)
Antifongiques/administration et posologie , Systèmes de délivrance de médicaments , Miconazole/administration et posologie , Animaux , Préparation de médicament , Stabilité de médicament , Femelle , Souris , Miconazole/composition chimique , Nanogels , Polymères/composition chimique , Spectroscopie infrarouge à transformée de Fourier , Viscosité
17.
J Chromatogr Sci ; 57(10): 867-873, 2020 Jan 17.
Article de Anglais | MEDLINE | ID: mdl-31602483

RÉSUMÉ

Nadifloxacin, mometasone furoate and miconazole nitrate are formulated together as a topical antifungal dosage form. In this work, a reversed-phase ultra-performance liquid chromatographic method coupled with a diode array detector (RP-UPLC-DAD) was developed and validated to determine nadifloxacin, mometasone furoate and miconazole nitrate simultaneously in their bulk powder, in pharmaceutical preparation and in spiked human plasma samples. Separation was achieved on an ACQUITY UPLC C18 column of 2.2 µm particle size (2.1 × 100 mm) via isocratic elution using a mobile phase consisting of methanol, acetonitrile and water with ratio (50:20:30; v/v/v) and 0.1 g ammonium acetate, then pH was adjusted to (7.00) using acetic acid, flow rate 0.6 mL/min, temperature 30°C and UV detection at 220 nm. The method is linear in a range from 5 to 400 µg/mL for both nadifloxacin and miconazole nitrate and from 20 to 500 µg/mL for mometasone furoate. The method was validated according to the ICH guidelines then applied successfully to determine the mentioned drugs in their pharmaceutical preparation and spiked human plasma samples. For plasma samples, the results showed that the method can determine nadifloxacin, mometasone furoate and miconazole nitrate in human plasma samples with high accuracy and precision.


Sujet(s)
Chromatographie en phase liquide à haute performance/méthodes , Fluoroquinolones/analyse , Miconazole/analyse , Furoate de mométasone/analyse , Quinolizines/analyse , Chromatographie en phase inverse , Fluoroquinolones/sang , Fluoroquinolones/composition chimique , Humains , Limite de détection , Modèles linéaires , Miconazole/sang , Miconazole/composition chimique , Furoate de mométasone/sang , Furoate de mométasone/composition chimique , Quinolizines/sang , Quinolizines/composition chimique , Reproductibilité des résultats
18.
Chem Pharm Bull (Tokyo) ; 67(2): 106-111, 2019.
Article de Anglais | MEDLINE | ID: mdl-30713269

RÉSUMÉ

The purpose of this study was to prepare poly(lactide-co-glycolide) (PLGA) microspheres (MS) loaded with itraconazole (ITCZ) or miconazole (MCZ) under different evaporation temperatures (25 or 40°C) using an oil-in-water emulsion solvent evaporation method in order to evaluate the initial burst release of drug. Loading efficiencies were comparatively good and the diameters of prepared drug-loaded PLGA MS were around 20 µm in all formulations. The release rates of ITCZ-PLGA MS prepared at 40°C showed a significantly restricted release profile compared with the corresponding ITCZ-PLGA MS prepared at 25°C. This difference in release rate of ITCZ was thought to be caused by the self-healing effect of PLGA, as the glass transition temperature of PLGA is around 40°C. With respect to the MCZ-PLGA MS, the initial burst release was similar in formulations prepared at both 25 and 40°C. Scanning electron microscope results suggested that the initial burst release was due to the localization of MCZ on the surface of MCZ-PLGA MS at higher concentrations. Differential scanning calorimetry measurements suggested complete amorphization of MCZ in MCZ-PLGA MS, whereas crystalline ITCZ was detected in the ITCZ-PLGA MS. This complete amorphization of MCZ is considered to be one of the reasons for the initial burst release.


Sujet(s)
Vecteurs de médicaments/composition chimique , Itraconazole , Miconazole , Microsphères , Polyglactine 910 , Calorimétrie différentielle à balayage , Préparation de médicament , Itraconazole/composition chimique , Miconazole/composition chimique
19.
Colloids Surf B Biointerfaces ; 174: 409-415, 2019 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-30481701

RÉSUMÉ

OBJECTIVES: In this study, polymeric nanoparticles based on chitosan incorporating the antifungal miconazole nitrate were fabricated and testedin vivo using murine vulvovaginal candidiasis. METHODS: Nanoparticles prepared by the ionotropic gelation method presented 200 to 300 nm diameter and polydispersity indexes ranging from 0.2 to 0.4. The nanoparticles were prepared to incorporate 63.9 mg/mL of miconazole nitrate to be testedin vivo. Murine vulvovaginal candidiasis was standardized using estradiol valerate before the animals were challenged by Candida albicans. RESULTS: The treatment using chitosan nanoparticles within miconazole nitrate presented the same therapeutic efficacy as miconazole nitrate in a commercial cream formulation, however using the antifungal content about seven-fold lower. This increase in the miconazole nitrate's therapeutic efficacy is may be due to the down-regulation of interleukin 10 (IL-10) expression. CONCLUSIONS: Our data represent a proof of concept that can be exploited to achieve an alternative and promising therapy for the treatment of vulvovaginal candidiasis.


Sujet(s)
Antifongiques/pharmacologie , Candida albicans/effets des médicaments et des substances chimiques , Candidose vulvovaginale/traitement médicamenteux , Chitosane/composition chimique , Miconazole/pharmacologie , Nanoparticules/administration et posologie , Administration par voie vaginale , Animaux , Antifongiques/composition chimique , Candidose vulvovaginale/microbiologie , Femelle , Humains , Souris , Souris de lignée BALB C , Miconazole/composition chimique , Nanoparticules/composition chimique
20.
Med Mycol ; 57(1): 52-62, 2019 Jan 01.
Article de Anglais | MEDLINE | ID: mdl-29361177

RÉSUMÉ

Vulvovaginal candidiasis (VVC) is caused mainly by the opportunistic fungus Candida albicans, and its yeast to hyphae transition is considered a major virulence factor. Farnesol is a molecule that inhibits yeast to hyphae transition. The increased incidence of VVC has influenced a need for developing new therapeutic strategies. The objective was to develop a mucoadhesive nanostructured system composed of miconazole and farnesol co-encapsulated within chitosan nanoparticles. The miconazole presented a minimal inhibitory concentration (MIC) of 1 µg/ml against C. albicans. The farnesol was capable of inhibiting yeast to hyphae transition at levels greater or equal to 300 µM. The combination of miconazole and farnesol showed no change in miconazole MIC. Chitosan nanoparticles containing miconazole and farnesol were prepared by ionic gelation and showed favorable characteristics for use on mucous membranes. They showed size variation and polydispersion index (PDI) after 30 days, but the efficiency of drug encapsulation was maintained. Regarding toxicity in cultured fibroblasts (BALB/c 3T3) the nanoparticles were considered nontoxic. The nanoparticles showed antifungal activity against the C. albicans strain used with MICs of 2.5 µg/ml and 2 µg/ml for nanoparticles containing miconazole or miconazole/farnesol, respectively. Nanoparticles containing farnesol inhibited yeast to hyphae transition at concentrations greater than or equal to 240 µM. The in vivo antifungal activity was assessed in the murine model for VVC. The results suggested that chitosan nanoparticles containing miconazole and farnesol were effective at inhibiting fungal proliferation. Additionally, chitosan nanoparticles containing farnesol were capable of decreasing the pathogenicity of infection, demonstrated through the absence of inflammation.


Sujet(s)
Candida albicans/effets des médicaments et des substances chimiques , Candidose vulvovaginale/traitement médicamenteux , Farnésol , Miconazole , Nanoparticules/composition chimique , Animaux , Antifongiques/synthèse chimique , Antifongiques/pharmacologie , Antifongiques/usage thérapeutique , Cellules BALB 3T3 , Candida albicans/croissance et développement , Candidose vulvovaginale/anatomopathologie , Capsules , Chitosane/composition chimique , Modèles animaux de maladie humaine , Farnésol/composition chimique , Farnésol/pharmacologie , Farnésol/usage thérapeutique , Femelle , Souris , Souris de lignée BALB C , Miconazole/composition chimique , Miconazole/pharmacologie , Miconazole/usage thérapeutique , Tests de sensibilité microbienne , Viabilité microbienne/effets des médicaments et des substances chimiques , Nanoparticules/usage thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE